ClinicalTrials.gg
CompletedNCT01772147Updated Mar 23, 2017Results posted

Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.

A Phase 3 interventional study of Umeclidinium bromide 62.5mcg and Umeclidinium bromide 125mcg in Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline. Completed at 55 sites in 5 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2017-03-23.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
608
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline — 7 open to participants now, 8 under way, 5 of them phase 3. Pulmonary Disease, Chronic Obstructive · GlaxoSmithKline.

Enrollment
50th of 236
608 · median 101
Started
2013
with 19 others
Phase 3
65 of 276
5 open now
Registered
164th of 276
by date

Among the 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline, this one is the 50th largest by enrollment of the 236 interventional ones that give a count, is one of 20 that started in 2013, is one of 65 in phase 3, and was the 164th registered.

Pulmonary Disease, Chronic Obstructive

5,526 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

7 of the 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline, or all of them as a file.
02

Study summary

The purpose of this 12 week study is to evaluate the effects of the addition of umeclidinium bromide (62.5mcg) once-daily to fluticasone propionate (250/50mcg) twice-daily and umeclidinium bromide (125mcg) once-daily to fluticasone propionate (250/50mcg) twice-daily with placebo when added to fluticasone propionate (250/50mcg) twice-daily on lung function, COPD-related health status assessments and safety in COPD subjects.

Read the detailed description

This is a multicenter, randomized, double-blind, parallel-group study. Subjects who meet the eligibility criteria at screening and meet the randomization criteria at the end of a 4 week run-in period will enter a 12 week treatment period. There will be a 7 day follow-up period after the treatment period.

03

Conditions studied

  • Pulmonary Disease, Chronic Obstructive
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type of subject: Outpatient.
  • : A signed and dated written informed consent prior to study participation.
  • Age: Subjects 40 years of age or older at Visit 1.
  • Gender: Male or female subjects. A female is eligible to enter and participate if of non-, or if of child bearing potential, has a megative serum pregnancy test at screening, and agrees to one of the acceptable methods listed in the protocol, used consistently and correctly.
  • Diagnosis: An established clinical history of in accordance with the definition by the American Thoracic Society/European Respiratory Society.
  • Smoking History: Current or former cigarette smokers with a history of cigarette smoking of ≥10 pack-years [number of pack years = (number of cigarettes per day / 20) x number of years smoked (e.g., 20 cigarettes per day for 10 years, or 10 cigarettes per day for 20 years)]. Former smokers are defined as those who have stopped smoking for at least 6 months prior to Visit 1. Pipe and/or cigar use cannot be used to calculate pack year history.
  • Severity of Disease: A pre and post-albuterol/salbutamol /FVC ratio of \<0.70 and a pre and post-albuterol/salbutamol FEV1 of ≤70% of predicted normal values at Visit 1 (Screening) calculated using Nutrition Health and Examination Survey (NHANES) III reference equations.
  • Dyspnea: A score of ≥2 on the mMRC Dyspnea Scale at Visit 1.

Exclusion criteria

Exclusion Criteria:

  • -Pregnancy: Women who are pregnant or lactating or are planning on becoming pregnant during the study.
  • Asthma: A current diagnosis of asthma.
  • Other Respiratory Disorders: Known α-1 antitrypsin deficiency, active lung infections (such as tuberculosis), and lung cancer are absolute exclusionary conditions. A subject who, in the opinion of the investigator, has any other significant respiratory conditions in addition to should be excluded. Examples may include bronchiectasis, pulmonary hypertension, sarcoidosis, or interstitial lung disease.
  • Other Diseases/Abnormalities: Subjects with historical or current evidence of clinically significant cardiovascular, neurological, psychiatric, renal, hepatic, immunological, endocrine (including uncontrolled diabetes or thyroid disease) or hematological abnormalities that are uncontrolled and/or a previous history of cancer in remission for \<5 years prior to Visit 1 (localized carcinoma of the skin that has been resected for cure is not exclusionary). Significant is defined as any disease that,in the opinion of the investigator, would put the safety of the subject at risk through participation, or which would affect the efficacy or safety analysis if the disease/condition exacerbated during the study.
  • : Any history of allergy or to any anticholinergic/muscarinic receptor antagonist, beta2-agonist, sympathomimetic, (intranasal, inhaled or systemic) lactose/milk protein or magnesium stearate, or a medical condition such as narrow-angle glaucoma, prostatic hypertrophy or bladder neck obstruction that, in the opinion of the study physician contraindicates study participation or use of an inhaled anticholingeric.
  • Hospitalization: Hospitalization for COPD or pneumonia within 12 weeks prior to Visit 1.
  • Lung Resection: Subjects with lung volume reduction surgery within the 12 months prior to Visit 1.
  • 12-Lead : An abnormal and significant ECG finding from the 12-lead ECG conducted at Visit 1. Investigators will be provided with ECG reviews conducted by a centralized independent cardiologist to assist in evaluation of subject eligibility. Specific ECG findings that preclude subject eligibility are listed in Appendix 4. The study investigator will determine the medical significance of any ECG abnormalities not listed in Appendix 4.
  • Medication Prior to Spirometry: Unable to withhold albuterol/salbutamol for the 4 hour period required prior to spirometry testing at each study visit.
  • Medications Prior to Screening: use of certain medications for the protocol-specific times prior to Visit 1.

Oxygen: Use of long-term oxygen therapy (LTOT) described as oxygen therapy prescribed for greater than 12 hours a day. As-needed oxygen use (i.e., ≤12 hours per day) is not exclusionary.

  • Nebulized Therapy: Regular use (prescribed for use every day, not for as-needed use) of short-acting bronchodilators (e.g., albuterol/salbutamol) via nebulized therapy.
  • Pulmonary Rehabilitation Program: Participation in the acute phase of a pulmonary rehabilitation program within 4 weeks prior to Visit 1. Subjects who are in the maintenance phase of a pulmonary rehabilitation program are not excluded.
  • Drug or Alcohol Abuse: A known or suspected history of alcohol or drug abuse within 2 years prior to Visit 1.
  • Affiliation with Investigator Site: A subject will not be eligible for this study if he/she is an immediate family member of the participating investigator, subinvestigator, study coordinator, or employee of the participating investigator.
  • Inability to read: In the opinion of the investigator, any subject who is unable to read and/or would not be able to complete a questionnaire.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
608 participants (actual)

Study arms

  • Experimental
    Umeclidinium bromide

    Long-acting muscarinic antagonist (LAMA)

    Drug: Umeclidinium bromide 62.5mcg · Drug: Umeclidinium bromide 125mcg

  • Active comparator
    Fluticasone propionate/Salmeterol

    Inhaled corticosteroid (ICS)/Long-acting beta agonist (LABA)

    Drug: Fluticasone propionate 250mcg/Salmeterol 50mcg

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Trough Forced Expiratory Volume in One Second (FEV1) on Day 85

    FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on Treatment Day 85 is defined as the mean of the FEV1 values obtained 23 and 24 hours after dosing on Treatment Day 84 (i.e., at Week 12). Baseline trough FEV1 is the mean of the two assessments made at -30 and -5 minutes (min) pre-dose on Treatment Day 1. Change from Baseline was calculated as the Day 85 value minus the Baseline value. Analysis was performed using a repeated measures model with covariates of treatment, Baseline (mean of the two assessments made at -30 and -5 min pre-dose on Treatment Day 1), smoking status, day, day by Baseline, and day by treatment interactions.

    Time frame: Baseline and Day 85

Secondary outcomes

  1. Change From Baseline in Weighted Mean 0-6 Hour FEV1 Obtained Post-dose at Day 84

    FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. The weighted mean FEV1 was derived by calculating the area under the curve, and then dividing the value by the relevant time interval. The weighted mean was calculated using the 6-hour serial FEV1 measurements at Day 84, which included pre-dose, and post-dose at 15 min, 30 min, 1 hour, 3 hours, and 6 hours. Baseline trough FEV1 is the mean of the two assessments made at -30 and -5 min pre-dose on Treatment Day 1. Change from Baseline was calculated as the Day 84 value minus the Baseline value. Analysis was performed using a repeated measures model with covariates of treatment, Baseline (mean of the two assessments made at -30and -5 min pre-dose on Treatment Day 1), smoking status, day, day by Baseline, and day by treatment interactions.

    Time frame: Baseline and Day 84

  2. Change From Baseline in the Mean Percentage of Rescue-free Days Over Weeks 1-12

    A rescue-free day is defined as a day on which no rescue medication was taken. Baseline calculations include a period of the later of 27 days before Visit 2 and the day after Visit 1, up to and including Day 1. The Weeks 1-12 calculations include a period from Study Day 2 up to the earlier of Study Day 85 and the day before Visit 7. Change from Baseline was calculated as the Weeks 1-12 value minus the Baseline value.

    Time frame: Baseline and Weeks 1- 12

  3. Change From Baseline in the Mean Number of Puffs Per Day of Rescue Albuterol/Salbutamol Over Weeks 1-12

    The mean number of puffs per day of rescue albuterol/salbutamol at Baseline and on-treatment was recorded. The total puffs of rescue albuterol/salbutamol for each day was calculated as: (number of puffs + \[2 \* number of nebules\]). Baseline calculations include a period of the later of 27 days before Visit 2 and the day after Visit 1, up to and including Day 1. The Weeks 1-12 calculations include a period from Study Day 2 up to the earlier of Study Day 85 and the day before Visit 7. Change from Baseline was calculated as the Weeks 1-12 value minus the Baseline value. Analysis was performed using an analysis of covariance (ANCOVA) model with covariates of treatment, Baseline (mean during the 4 weeks prior to Day 1), and smoking status.

    Time frame: Baseline and Weeks1- 12

07

Results

Posted Apr 21, 2014

Participant flow

A total of 872 participants who met the eligibility criteria at Screening (Visit 1) started a 28-day Run-in Period, in which they received open-label fluticasone propionate and salmeterol (FSC) 250/50 micrograms (µg), prior to being randomized to a 12-week randomized Treatment Period.

Participant flow — Overall Study
MilestonePlacebo QD + FSC 250/50 µg BIDUMEC 62.5 µg QD + FSC 250/50 µg BIDUMEC 125 µg QD + FSC 250/50 µg BID
Started201203202
Completed170178184
Not completed312518
Withdrew: Adverse event13106
Withdrew: Withdrew consent784
Withdrew: Lost to follow-up101
Withdrew: Protocol deviation211
Withdrew: Lack of efficacy866

Outcome measures

PrimaryChange From Baseline in the Trough Forced Expiratory Volume in One Second (FEV1) on Day 85

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 on Treatment Day 85 is defined as the mean of the FEV1 values obtained 23 and 24 hours after dosing on Treatment Day 84 (i.e., at Week 12). Baseline trough FEV1 is the mean of the two assessments made at -30 and -5 minutes (min) pre-dose on Treatment Day 1. Change from Baseline was calculated as the Day 85 value minus the Baseline value. Analysis was performed using a repeated measures model with covariates of treatment, Baseline (mean of the two assessments made at -30 and -5 min pre-dose on Treatment Day 1), smoking status, day, day by Baseline, and day by treatment interactions.

Time frame:
Baseline and Day 85
Reported as:
Least squares mean · Liters
Change From Baseline in the Trough Forced Expiratory Volume in One Second (FEV1) on Day 85
LitersPlacebo QD + FSC 250/50 µg BIDUMEC 62.5 µg QD + FSC 250/50 µg BIDUMEC 125 µg QD + FSC 250/50 µg BID
Change From Baseline in the Trough Forced Expiratory Volume in One Second (FEV1) on Day 85-0.001 ± 0.01360.126 ± 0.01330.147 ± 0.0132
Statistical analysis
  • Placebo QD + FSC 250/50 µg BID vs UMEC 62.5 µg QD + FSC 250/50 µg BID · Mixed Models Analysis · p = <0.001 · Mean difference (net): 0.127 · 95% CI 0.089 to 0.164
  • Placebo QD + FSC 250/50 µg BID vs UMEC 125 µg QD + FSC 250/50 µg BID · Mixed Models Analysis · p = <0.001 · Mean difference (net): 0.148 · 95% CI 0.111 to 0.185
SecondaryChange From Baseline in Weighted Mean 0-6 Hour FEV1 Obtained Post-dose at Day 84

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. The weighted mean FEV1 was derived by calculating the area under the curve, and then dividing the value by the relevant time interval. The weighted mean was calculated using the 6-hour serial FEV1 measurements at Day 84, which included pre-dose, and post-dose at 15 min, 30 min, 1 hour, 3 hours, and 6 hours. Baseline trough FEV1 is the mean of the two assessments made at -30 and -5 min pre-dose on Treatment Day 1. Change from Baseline was calculated as the Day 84 value minus the Baseline value. Analysis was performed using a repeated measures model with covariates of treatment, Baseline (mean of the two assessments made at -30and -5 min pre-dose on Treatment Day 1), smoking status, day, day by Baseline, and day by treatment interactions.

Time frame:
Baseline and Day 84
Reported as:
Least squares mean · Liters
Change From Baseline in Weighted Mean 0-6 Hour FEV1 Obtained Post-dose at Day 84
LitersPlacebo QD + FSC 250/50 µg BIDUMEC 62.5 µg QD + FSC 250/50 µg BIDUMEC 125 µg QD + FSC 250/50 µg BID
Change From Baseline in Weighted Mean 0-6 Hour FEV1 Obtained Post-dose at Day 840.052 ± 0.01370.196 ± 0.01350.217 ± 0.0133
SecondaryChange From Baseline in the Mean Percentage of Rescue-free Days Over Weeks 1-12

A rescue-free day is defined as a day on which no rescue medication was taken. Baseline calculations include a period of the later of 27 days before Visit 2 and the day after Visit 1, up to and including Day 1. The Weeks 1-12 calculations include a period from Study Day 2 up to the earlier of Study Day 85 and the day before Visit 7. Change from Baseline was calculated as the Weeks 1-12 value minus the Baseline value.

Time frame:
Baseline and Weeks 1- 12
Reported as:
Mean · Percentage of days
Change From Baseline in the Mean Percentage of Rescue-free Days Over Weeks 1-12
Percentage of daysPlacebo QD + FSC 250/50 µg BIDUMEC 62.5 µg QD + FSC 250/50 µg BIDUMEC 125 µg QD + FSC 250/50 µg BID
Change From Baseline in the Mean Percentage of Rescue-free Days Over Weeks 1-121.9 ± 27.388.4 ± 30.2315.2 ± 28.25
SecondaryChange From Baseline in the Mean Number of Puffs Per Day of Rescue Albuterol/Salbutamol Over Weeks 1-12

The mean number of puffs per day of rescue albuterol/salbutamol at Baseline and on-treatment was recorded. The total puffs of rescue albuterol/salbutamol for each day was calculated as: (number of puffs + \[2 \* number of nebules\]). Baseline calculations include a period of the later of 27 days before Visit 2 and the day after Visit 1, up to and including Day 1. The Weeks 1-12 calculations include a period from Study Day 2 up to the earlier of Study Day 85 and the day before Visit 7. Change from Baseline was calculated as the Weeks 1-12 value minus the Baseline value. Analysis was performed using an analysis of covariance (ANCOVA) model with covariates of treatment, Baseline (mean during the 4 weeks prior to Day 1), and smoking status.

Time frame:
Baseline and Weeks1- 12
Reported as:
Least squares mean · puffs
Change From Baseline in the Mean Number of Puffs Per Day of Rescue Albuterol/Salbutamol Over Weeks 1-12
puffsPlacebo QD + FSC 250/50 µg BIDUMEC 62.5 µg QD + FSC 250/50 µg BIDUMEC 125 µg QD + FSC 250/50 µg BID
Change From Baseline in the Mean Number of Puffs Per Day of Rescue Albuterol/Salbutamol Over Weeks 1-12-0.2 ± 0.10-0.4 ± 0.10-0.7 ± 0.10

Adverse events

Collected over On-treatment serious adverse events (SAEs) and non-serious adverse events (AEs) are defined as those events occurring while participants were on treatment or those events with an onset during the follow-up period (up to 13 weeks).. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo QD + FSC 250/50 µg BID—15/201 (7.5%)18/201 (9%)
UMEC 62.5 µg QD + FSC 250/50 µg BID—6/203 (3%)13/203 (6.4%)
UMEC 125 µg QD + FSC 250/50 µg BID—6/202 (3%)16/202 (7.9%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventPlacebo QD + FSC 250/50 µg BIDUMEC 62.5 µg QD + FSC 250/50 µg BIDUMEC 125 µg QD + FSC 250/50 µg BID
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders8/2013/2031/202
PneumoniaInfections and infestations4/2013/2033/202
Infective exacerbation of chronic obstructive airways diseasInfections and infestations2/2010/2030/202
InfluenzaInfections and infestations1/2010/2030/202
Lobar pneumoniaInfections and infestations1/2010/2030/202
Septic shockInfections and infestations1/2010/2030/202
Acute respiratory failureRespiratory, thoracic and mediastinal disorders1/2010/2030/202
Respiratory failureRespiratory, thoracic and mediastinal disorders1/2010/2030/202
Cardiac arrestCardiac disorders1/2010/2030/202
Acute myocardial infarctionCardiac disorders1/2010/2030/202
Most frequent other events
Most frequent other events
EventPlacebo QD + FSC 250/50 µg BIDUMEC 62.5 µg QD + FSC 250/50 µg BIDUMEC 125 µg QD + FSC 250/50 µg BID
NasopharyngitisInfections and infestations9/2016/20310/202
HeadacheNervous system disorders9/2019/2036/202

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Placebo QD + FSC 250/50 µg BIDUMEC 62.5 µg QD + FSC 250/50 µg BIDUMEC 125 µg QD + FSC 250/50 µg BIDTotal
Mean65.7 ± 7.9264.5 ± 8.3165.5 ± 7.8965.2 ± 8.04
Sex: Female, Male
Sex: Female, Male(Participants)Placebo QD + FSC 250/50 µg BIDUMEC 62.5 µg QD + FSC 250/50 µg BIDUMEC 125 µg QD + FSC 250/50 µg BIDTotal
Female786382223
Male123140120383
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo QD + FSC 250/50 µg BIDUMEC 62.5 µg QD + FSC 250/50 µg BIDUMEC 125 µg QD + FSC 250/50 µg BIDTotal
African American/African Heritage35412
American Indian or Alaska Native0101
Japanese/East Asian Heritage/South East Asian37332797
White161164171496
08

Study locations

55 sites
  • GSK Investigational Site
    Mobile, Alabama 36608, United States
  • GSK Investigational Site
    Phoenix, Arizona 85006, United States
  • GSK Investigational Site
    Huntington Beach, California 92647, United States
  • GSK Investigational Site
    DeLand, Florida 32720, United States
  • GSK Investigational Site
    Orlando, Florida 32822, United States
  • GSK Investigational Site
    Tampa, Florida 33603, United States
  • GSK Investigational Site
    Coeur D'Alene, Idaho 83814, United States
  • GSK Investigational Site
    Sunset, Louisiana 70584, United States
  • GSK Investigational Site
    St. Charles, Missouri 63301, United States
  • GSK Investigational Site
    Charlotte, North Carolina 28207, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45245, United States
  • GSK Investigational Site
    Rock Hill, South Carolina 29732, United States
  • GSK Investigational Site
    Seneca, South Carolina 29678, United States
  • GSK Investigational Site
    Spartanburg, South Carolina 29303, United States
  • GSK Investigational Site
    Newport News, Virginia 23606, United States
  • GSK Investigational Site
    Richmond, Virginia 23229, United States
  • GSK Investigational Site
    Richmond, Virginia 23249, United States
  • GSK Investigational Site
    Concepción, Región Del Biobio 4070038, Chile
  • GSK Investigational Site
    Puente Alto - Santiago, Región Metro De Santiago 8207257, Chile
  • GSK Investigational Site
    Santiago, Región Metro De Santiago 7500710, Chile
  • GSK Investigational Site
    Santiago, Región Metro De Santiago 7500800, Chile
  • GSK Investigational Site
    Santiago, Región Metro De Santiago 8880465, Chile
  • GSK Investigational Site
    Santiago, Región Metro De Santiago, Chile
  • GSK Investigational Site
    Talca, Región Metro De Santiago 3460001, Chile
  • GSK Investigational Site
    Viña del Mar, Valparaíso 2520024, Chile
  • GSK Investigational Site
    Viña del Mar, Valparaíso, Chile
  • GSK Investigational Site
    Karlovy Vary, 360 09, Czech Republic
  • GSK Investigational Site
    Kralupy nad Vltavou, 278 01, Czech Republic
  • GSK Investigational Site
    Lovosice, 410 02, Czech Republic
  • GSK Investigational Site
    Olomouc, 772 00, Czech Republic
  • GSK Investigational Site
    Ostrava - Poruba, 70868, Czech Republic
  • GSK Investigational Site
    Plzen, 301 00, Czech Republic
  • GSK Investigational Site
    Plzen, 323 00, Czech Republic
  • GSK Investigational Site
    Praha 4, 140 46, Czech Republic
  • GSK Investigational Site
    Praha 5, 150 00, Czech Republic
  • GSK Investigational Site
    Praha 7, 170 00, Czech Republic
  • GSK Investigational Site
    Tabor, 390 19, Czech Republic
  • GSK Investigational Site
    Teplice, 415 10, Czech Republic
  • GSK Investigational Site
    Daegu, 705-717, Korea, Republic of
  • GSK Investigational Site
    Seongnam-si, Gyeonggi-do, 463-707, Korea, Republic of
  • GSK Investigational Site
    Seoul, 110-744, Korea, Republic of
  • GSK Investigational Site
    Seoul, 130-848, Korea, Republic of
  • GSK Investigational Site
    Seoul, 134-701, Korea, Republic of
  • GSK Investigational Site
    Seoul, 143-729, Korea, Republic of
  • GSK Investigational Site
    Seoul, 152-703, Korea, Republic of
  • GSK Investigational Site
    Seoul, 158-710, Korea, Republic of
  • GSK Investigational Site
    Elblag, 82-300, Poland
  • GSK Investigational Site
    Gdynia, 81-384, Poland
  • GSK Investigational Site
    Grudziadz, 86-300, Poland
  • GSK Investigational Site
    Inowroclaw, 88-100, Poland
  • GSK Investigational Site
    Krakow, 31-024, Poland
  • GSK Investigational Site
    Ostrow Wielkopolski, 63-400, Poland
  • GSK Investigational Site
    Pila, 64-920, Poland
  • GSK Investigational Site
    Warszawa, 01-192, Poland
  • GSK Investigational Site
    Wroclaw, 50-088, Poland
09

References and documents

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2013, a primary completion of Aug 2013 and a completion of Aug 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2014, 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2013
First posted
Jan 21, 2013
Start
Jan 2013
Primary completionActual
Aug 2013
CompletionActual
Aug 2013
Results first posted
Apr 21, 2014
Last update
Mar 23, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01772147
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jan 21, 2013
Start date
Jan 2013
Primary completion
Aug 2013
Completion
Aug 2013
Results posted
Apr 21, 2014
Last update
Mar 23, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Umeclidinium bromide

Start the discussion